Welcome to LookChem.com Sign In|Join Free
  • or
Cbz-2,6-Difluoro-L-Phenylalanine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

627910-22-9

Post Buying Request

627910-22-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

627910-22-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 627910-22-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,7,9,1 and 0 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 627910-22:
(8*6)+(7*2)+(6*7)+(5*9)+(4*1)+(3*0)+(2*2)+(1*2)=159
159 % 10 = 9
So 627910-22-9 is a valid CAS Registry Number.

627910-22-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-2-benzyloxycarbonylamino-3-(2,6-difluorophenyl)propionic acid

1.2 Other means of identification

Product number -
Other names 2(S)-benzyloxycarbonylamino-3-(2,6-difluoro-phenyl)propionic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:627910-22-9 SDS

627910-22-9Relevant academic research and scientific papers

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 46, (2008/06/13)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 56-57, (2010/10/20)

The present invention is directed to a novel process for preparing certain cysteine protease inhibitors.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 56, (2008/06/13)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 43, (2010/02/11)

The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in p

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 40, (2010/02/09)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu

CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 43, (2010/02/07)

The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceut

PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page 63, (2010/11/30)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 627910-22-9